...
首页> 外文期刊>The Journal of molecular diagnostics: JMD >Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels
【24h】

Somatic Tumor Variant Filtration Strategies to Optimize Tumor-Only Molecular Profiling Using Targeted Next-Generation Sequencing Panels

机译:体细胞肿瘤变异过滤策略,以优化靶的下一代测序板优化仅肿瘤的分子分析

获取原文
获取原文并翻译 | 示例

摘要

A common approach in clinical diagnostic laboratories to variant assessment from tumor molecular profiling is sequencing of genomic DNA extracted from both tumor (somatic) and normal (germline) tissue, with subsequent variant comparison to identify true somatic variants with potential impact on patient treatment or prognosis. However, challenges exist in paired tumor-normal testing, including increased cost of dual sample testing and identification of germline cancer predisposing variants. Alternatively, somatic variants can be identified by in silico tumor-only variant filtration precluding the need for matched normal testing. The barrier to tumor-only variant filtration is defining a reliable approach, with high sensitivity and specificity to identify somatic variants. In this study, we used retrospective data sets from paired tumor-normal samples tested on small (48 gene) and large (555 gene) targeted next-generation sequencing panels, to model algorithms for tumor-only variants classification. The optimal algorithm required an ordinal filtering approach using information from variant population databases (1000 Genomes Phase 3, ESP6500, ExAC), clinical mutation databases (ClinVar), and information on recurring clinically relevant somatic variants. Overall the tumor-only variant filtration strategy described in this study can define clinically relevant somatic variants from tumor-only analysis with sensitivity of 97% to 99% and specificity of 87% to 94%, and with significant potential utility for clinical laboratories implementing tumor-only molecular profiling.
机译:临床诊断实验室的常见方法是肿瘤分子分析的变异评估是从肿瘤(体细胞)和正常(种系)组织中提取的基因组DNA的测序,随后的变异比较,以鉴定具有对患者治疗或预后潜在影响的真正体制变体。然而,挑战存在于成对的肿瘤正常检测中,包括增加的双样本测试成本和种系癌预处理变异的鉴定。或者,可以通过在硅肿瘤的肿瘤的变体过滤中鉴定体体变体,这排除了匹配的正常测试的需要。对肿瘤变异过滤的屏障是定义可靠的方法,具有高灵敏度和特异性来识别体躯体变体。在这项研究中,我们使用从对小(48个基因)和大(555个基因)的成对的肿瘤正常样本中的回顾性数据集,靶向下一代测序板的靶向下一代测序板的模型算法进行了模型算法。最佳算法需要使用来自变体群体数据库的信息(1000个基因组阶段3,ESP6500,EXAC),临床突变数据库(Clarvar)以及关于经常性临床相关的体变形的信息的信息。总体而言,本研究中描述的肿瘤变异过滤策略可以在肿瘤上分析中描述的临床相关的体变形,其敏感性为97%至99%,特异性为87%至94%,以及用于实施肿瘤的临床实验室的显着潜在效用 - 单分子分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号